Little Dog client ViaCyte made headlines this month with the announcement they have secured $80 million to support their development of stem cell-derived cell replacement therapies, with a focus on the treatment of insulin-requiring diabetes.  

Together with the recently announced strategic collaborations and transactions with W.L. Gore and Associates and CRISPR TherapeuticsViaCyte has secured commitments for more than $100 million of new financing in the second half of this year. The recent funding adds to the substantial financial support ViaCyte has received from the non-profit patient advocacy groups, JDRF and the California Institute for Regenerative Medicine. 

XconomyViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later 

Pin It on Pinterest